Sunshine Biopharma, Inc. (SBFM)
2.71
-0.08
(-2.87%)
USD |
NASDAQ |
Nov 06, 16:00
2.76
+0.05
(+1.85%)
After-Hours: 06:12
Sunshine Biopharma Enterprise Value : -12.73M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -12.73M |
| November 05, 2026 | -12.72M |
| November 04, 2026 | -12.74M |
| November 03, 2026 | -12.73M |
| November 02, 2026 | -12.73M |
| October 30, 2026 | -12.71M |
| October 29, 2026 | -12.66M |
| October 28, 2026 | -12.69M |
| October 27, 2026 | -12.70M |
| October 26, 2026 | -12.74M |
| October 23, 2026 | -12.70M |
| October 22, 2026 | -12.66M |
| October 21, 2026 | -12.54M |
| October 20, 2026 | -12.53M |
| October 19, 2026 | -12.48M |
| October 16, 2026 | -12.53M |
| October 15, 2026 | -12.51M |
| October 14, 2026 | -12.48M |
| October 13, 2026 | -12.49M |
| October 12, 2026 | -12.34M |
| October 09, 2026 | -12.25M |
| October 08, 2026 | -12.03M |
| October 07, 2026 | -11.39M |
| October 06, 2026 | -12.11M |
| October 05, 2026 | -12.05M |
| Date | Value |
|---|---|
| October 02, 2026 | -11.47M |
| October 01, 2026 | -11.42M |
| September 30, 2026 | -11.21M |
| September 29, 2026 | -11.18M |
| September 28, 2026 | -11.10M |
| September 25, 2026 | -11.04M |
| September 24, 2026 | -11.15M |
| September 23, 2026 | -10.97M |
| September 22, 2026 | -10.89M |
| September 21, 2026 | -10.89M |
| September 18, 2026 | -10.91M |
| September 17, 2026 | -11.05M |
| September 16, 2026 | -10.60M |
| September 15, 2026 | -10.60M |
| September 14, 2026 | -10.50M |
| September 11, 2026 | -10.53M |
| September 10, 2026 | -10.48M |
| September 09, 2026 | -10.38M |
| September 08, 2026 | -10.31M |
| September 04, 2026 | -10.33M |
| September 03, 2026 | -10.41M |
| September 02, 2026 | -10.26M |
| September 01, 2026 | -10.36M |
| August 31, 2026 | -10.38M |
| August 28, 2026 | -10.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.564M |
| Revenue (Quarterly) | 9.264M |
| Total Expenses (Quarterly) | 10.83M |
| EPS Diluted (Quarterly) | -22.91 |
| Gross Profit Margin (Quarterly) | 25.35% |
| Profit Margin (Quarterly) | -16.88% |
| Earnings Yield | -7.55K% |
| Normalized Earnings Yield | -6771.60 |